Valuation: Lundbeck

Market Cap 51.05B 7.64B 6.83B 6.32B 5.72B 10.71B 727B 10.88B 76.03B 30.07B 380B 28.66B 28.05B 1,203B P/E 2026 *
11.3x
P/E 2027 * 11.2x
Enterprise Value 54.98B 8.22B 7.35B 6.8B 6.16B 11.53B 783B 11.72B 81.88B 32.39B 409B 30.87B 30.21B 1,296B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.94x
Free-Float
30.74%
Yield 2026 *
3.02%
Yield 2027 * 2.71%
1 day-0.05%
1 week+8.80%
Current month+14.40%
1 month+11.40%
3 months+34.76%
6 months+39.17%
Current year+34.94%
1 week 44.9
Extreme 44.9
49.8
1 month 41.05
Extreme 41.05
49.8
Current year 31.4
Extreme 31.4
49.8
1 year 31.4
Extreme 31.4
49.8
3 years 23.3
Extreme 23.3
49.8
5 years 21.94
Extreme 21.935
49.8
10 years 21.94
Extreme 21.935
49.8
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 67 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+8.80% - - 7.65B
+0.48%+3.07%+54.69%+125.03% 1,135B
+0.49%+4.46%+39.31%+77.93% 635B
+0.13%+1.17%+25.42%+96.97% 505B
+1.43%+4.31%+48.28%+67.12% 378B
-3.03%-2.10%+59.78%+33.22% 358B
-0.41%+2.64%+23.58%+49.82% 295B
+0.23%+3.66%+2.45%+23.69% 266B
+0.29%+3.64%+51.26%+63.28% 237B
+1.33%+3.46%+31.45%+101.73% 193B
Average +0.11%+1.60%+37.36%+70.98% 444.85B
Weighted average by Cap. +0.18%+1.63%+41.32%+83.27%

Financials

2026 *2027 *
Net sales 25.94B 3.88B 3.47B 3.21B 2.91B 5.44B 369B 5.53B 38.63B 15.28B 193B 14.56B 14.25B 611B 26.21B 3.92B 3.51B 3.24B 2.94B 5.5B 373B 5.59B 39.04B 15.44B 195B 14.72B 14.4B 618B
Net income 4.62B 691M 618M 572M 518M 969M 65.73B 984M 6.88B 2.72B 34.38B 2.59B 2.54B 109B 4.66B 697M 623M 577M 522M 977M 66.32B 993M 6.94B 2.75B 34.69B 2.62B 2.56B 110B
Net Debt 3.93B 588M 526M 487M 441M 825M 55.95B 838M 5.85B 2.32B 29.27B 2.21B 2.16B 92.66B -218M -32.62M -29.17M -26.99M -24.44M -45.73M -3.1B -46.48M -325M -128M -1.62B -122M -120M -5.14B
Projected Income Statement - Annual - Lundbeck
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
27/10/26 DKK 48.85 -0.51% 73,099
23/10/26 DKK 49.10 +1.87% 58,747
22/10/26 DKK 48.20 +2.88% 41,925
21/10/26 DKK 46.85 +1.30% 67,329
20/10/26 DKK 46.25 +3.01% 96,761
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Lundbeck
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
52.10DKK
Average target price
50.96DKK
Spread / Average Target
-2.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lundbeck